First of all, after the close on Thursday, the company announced positive data from a depression treatment trial. Also, the issue moved higher on positive comments from CNBC's Jim Cramer.
After a higher open, it continued in that direction until peaking at $59.40 and reversing course.
That level is shy of its January 20 high of $61.56. The following day the issue sank to $33.69 following the announcement that ALKS5461 study for depression disorder did not meet its endpoint.
The ensuing decline off the high has found intraday support at $54.80 and now the issue is attempting to remain at the $57 handle.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.